Dr Standiford is the Medical Director for the Infection Control and Antimicrobial Effectiveness. As such, he provides physician oversight for the University of Maryland Medical Center’s antimicrobial stewardship and infection control programs. He is a Master in the
Dr Standiford is the Medical Director of the Antimicrobial Clinical Research Laboratory. The program performs clinical research with a focus on the prevention and treatment of hospital acquired infections and antimicrobial-resistant pathogens. Topics of investigation include central line associated infections, health care associated and community acquired pneumonia, skin and skin structure infections, infections caused by methicillin-resistant S aureus and Clostridium difficile diarrhea. He is an author of over 100 publications, of which the following are a few examples:
Prevention of Antimicrobial Resistance and the Effect of Host Factors on Outcome. Antimicrob Agents and Chemotherapy.37:1334-1342, 1993.
Hafner R, Inderlied CB, Peterson DM, Wright DJ, Standiford HC, Drusano G, Muth K, and the Division of AIDS Treatment Research Initiative Protocol 007 Study Group. Correlation of Quantitative Bone Marrow and Blood Cultures in AIDS Patients with Disseminated Mycobacterium avium Complex Infection. JID 180:438-47, 1999.
Wong MT, Kauffman CA, Standiford HC, Linden P, Fort G, Fuchs HJ, Porter SB, Wenzel RP and the Ramoplanin VRE Clinical Study Group. Effective suppression of vancomycin-resistant enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001:33:1476-1482.
Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, and Remington J. Worldwide Clinical Safety and Tolerability with Linezolid: Comparitor-Controlled Phase III Experience. Antimicrob Agents Chemother. 2003: 47; 24-31
Wright M.O., Hebden J.N., Harris A.D., Shanholtz C.B., Standiford H.C., Furuno J.P., Perencevich E.N. Aggressive control measures for resistant Acinetobacter baumanii and the impact on acquisition of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) in a medical icu. Infection Control and Epidemiology. 25:167-168. 2004
Wright M.O., Perencevich E.N., Novak C., Hebden J.N., Standiford H.C., Harris A.D. A preliminary assessment of an automated surveillance system for infection control. Infection Control Hosp Epidemiol. 25:325-32. 2004
Harris A.D., Nemoy L., Johnson J.A., Carnahan A.M., Smith D.L., Standiford H., Perencevich E.N. Co-carriage rates of VRE and ESBL-producing bacteria among a cohort of ICU patients: implications for an active surveillance program. Infection Control and Epidemiology. 25:105-108. 2004
Furuno JP, Perencevich EN, Johnson JA, Wright MO, McGregor JC, Nemoy LL, Roghmann M, Standiford HC, Hebden JN, Strauss SM, Harris AD. Patients at Risk for Vancomycin-Resistant Staphylococcus aureus: Co-colonization with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Emerg Infect Dis. 11: 1539-4, 2005